Aurobindo Pharma : Earnings Presentation-Q1 FY 2023-24

August 12, 2023

To	To
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza, Bandra Kurla Complex, Bandra (E),	Phiroz Jeejeebhoy Towers,
MUMBAI -400 051	25th floor, Dalal Street,
	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

Sub: Investor / Analysts Presentation

Please refer to our letter dated August 4, 2023, wherein we intimated the schedule of Investors/ Analysts call on August 14, 2023. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2023. The presentation is also being uploaded in the following weblink of the Company.

https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations

Please take the information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

Digitally signed by ADIREDDY BADDIGAM

Date: 2023.08.12 18:23:49 +05'30'

B. Adi Reddy

Company Secretary

Encl.: As above

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.

Tel : [phone] Fax: [phone].

Regd. off.: PlotNo. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel:[phone] Fax: [phone] Email: [e-mail] Website: www.aurobindo.com

Aurobindo Pharma Limited

Earnings Presentation

Q1FY24

Disclaimer

This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract, therefore.

This presentation contains statements that constitute "forward looking statements" including and without limitation, statements

relating to the implementation of strategic initiatives, and other statements relating to our future business developments and

economic performance.

While these forward-looking statements represent our judgment and future expectations concerning the development of our

business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and

other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance.

Aurobindo Pharma undertakes no obligation to publicly revise any forward-looking statements to reflect future events or

circumstances.

This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person.

2

Table of Contents

04 Q1FY24 Business & Financial Highlights

10 Financial Performance

13 Filings Snapshot

3

Q1FY24 Business & Financial Highlights

4